Science Business: The Promise, the Reality, and the Future of Biotech
| Author | : | |
| Rating | : | 4.86 (742 Votes) |
| Asin | : | 1591398401 |
| Format Type | : | paperback |
| Number of Pages | : | 256 Pages |
| Publish Date | : | 2014-01-31 |
| Language | : | English |
DESCRIPTION:
Seriously just fun to read Really just a wonderful introspective into the realm of the biotechnology sector. The writing style is excellent, entertaining, and very analytical. He does a fantastic job of illustrating the scientific challenges that make biotech unique. My favorite chapter in the first section (Section I) entitled, "The Science of the Business" was chapter Seriously just fun to read Elliot Kleiman Really just a wonderful introspective into the realm of the biotechnology sector. The writing style is excellent, entertaining, and very analytical. He does a fantastic job of illustrating the scientific challenges that make biotech unique. My favorite chapter in the first section (Section I) entitled, "The Science of the Business" was chapter 4, "Drug R&D and the Organizational Challenges". Here, he explains qui. , "Drug R&D and the Organizational Challenges". Here, he explains qui. Overly Technical - Loyd Eskildson Biotechnology has sometimes been suggested as a source of high-paying jobs to replace the millions of manufacturing jobs lost to globalization and automation. Gary Pisano's (Harvard Business School professor) "Science Business" explores the topic of biotech's failure to meet these expectations. His conclusions stress a need for organizational structures and financing that place greater emphasis on long-term learn. Jeff said Extrememly lucid, well thought out analysis. For my money, most business school professors write with a detached, dry atmosphere about business topics.Not Gary Pisano!He has a strong point of view that the ecosystem for biotech is not working well. His observations about why are right to the point and convincing.His prescriptions are well worth considering.If you're new to biotech, this is a great book to start out with. I would then proceed to Building Bio
-- The Wall Street Journal, January 3, 2007. "Pisano argues that as a business, the biotech sector hasn't matched the innovations of its science." -- BusinessWeek Online, December 20, 2006"Science Business" provides a fascinating history of pharmaceuticals and biotechnology
And he provides clear prescriptions for companies, investors, and policy makers seeking ways to improve the industry's performance. Pisano not only reveals the underlying causes of biotech's problems; he offers the most sophisticated analysis yet on how the industry works. The payoff? Valuable improvements in health care, and a shinier future for human well-being.. According to Pisano, the biotech industry's problems stem from its special character as a science-based business. Pisano answers this question by providing an incisive critique of the industry. Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. This character poses three unique business challenges: how to finance highly risky investments under profound uncertainty and long time horizons for R&D, how to learn rapidly enough to keep pace with advances in drug science knowledge, and how to integrate capabilities across a broad spectrum of scientific and technological knowledge bases.The key to fixing the industry? Business models, organisational structures, and financing arrangements that place greater emphasis on integration and long-term learning over shorter—term 'monetisation' of intellectual property. Pisano maintains that all industry players—biotech firms, investors, universities, pharmaceutical companies, government regulators—can play a role in righting the industry
Pisano is the Harry E. Professor of Business Administration and Head of the Technology and Operations Management unit at Harvard Business School.. Figgle Jr. Gary P